You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

45 Results
Drug
Other Name(s): Inlyta®
Dec 1969
Drug
Other Name(s): Tafinlar®
Dec 1969
Drug
Other Name(s): Giotrif®
Dec 1969
Drug
Other Name(s): Alecensaro®
Dec 1969
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
Exceptional Access Program
    aXitinib - For second or third line treatment of advanced renal cell carcinoma, according to clinical criteria
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
  • daBRAfenib - As monotherapy for the treatment of patients with BRAF V600 mutation-positive unresectable melanoma or metastatic disease, according to specific criteria
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    AFAtinib - For first-line monotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC), according to specific criteria
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
Exceptional Access Program
    pomalidomide - For patients with relapsed and/or refractory multiple myeloma, according to specific criteria.
ODB - General Benefit
    dexamethasone
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    daBRAfenib - In combination with trametinib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, according to specific clinical criteria
Exceptional Access Program
    trametinib - In combination with dabrafenib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, according to specific clinical criteria
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    alectinib - Treatment of non-small cell lung cancer, according to specific criteria
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Promyelocytic (APL)
Intent: Palliative, Curative
Funding:
Exceptional Access Program
    tretinoin (ATRA)
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Promyelocytic (APL)
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    tretinoin (ATRA)

Pages